Cargando…

Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy

INTRODUCTION: Locoregional interventional therapy including transcatheter arterial chemoembolization (TACE) and ablation are the current standard of treatment for early-to-mid-stage hepatocellular carcinoma (HCC). However, questions remain unanswered regarding the management of recurrence after loco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiao, Wenying, Wang, Qi, Hu, Caixia, Zhang, Yinghua, Li, Jianjun, Sun, Yu, Yuan, Chunwang, Wang, Wen, Liu, Biyu, Zhang, Yonghong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650042/ https://www.ncbi.nlm.nih.gov/pubmed/36389724 http://dx.doi.org/10.3389/fimmu.2022.1019772

Ejemplares similares

Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma
por: Wang, Qi, et al.
Publicado: (2022)

The Dynamic Changes of AFP From Baseline to Recurrence as an Excellent Prognostic Factor of Hepatocellular Carcinoma After Locoregional Therapy: A 5-Year Prospective Cohort Study
por: Wang, Qi, et al.
Publicado: (2021)

The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy
por: Wang, Qi, et al.
Publicado: (2022)

Dynamic Changes of Cytokine Profiles and Their Correlation With Tumor Recurrence Following Thermal Ablation in Hepatocellular Carcinoma
por: Guo, Dandan, et al.
Publicado: (2023)

Prognostic significance of globulin/low-density lipoprotein ratio in patients with hepatocellular carcinoma after local ablative therapy: a retrospective cohort study
por: Sun, Yu, et al.
Publicado: (2023)

Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance
por: Shi, Qin, et al.
Publicado: (2023)

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
por: Tang, Hui, et al.
Publicado: (2022)

Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors
por: Li, Jian, et al.
Publicado: (2023)

Predicting hepatocellular carcinoma early recurrence after ablation based on magnetic resonance imaging radiomics nomogram
por: Yang, Xiaozhen, et al.
Publicado: (2022)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis
por: Wang, Qi, et al.
Publicado: (2023)

Decidual macrophages derived NO downregulates PD-L1 in trophoblasts leading to decreased Treg cells in recurrent miscarriage
por: Zhang, Yonghong, et al.
Publicado: (2023)

Effect of HBsAg expression in liver tissue on prognosis of hepatocellular carcinoma after minimally invasive interventional therapy
por: Liu, Biyu, et al.
Publicado: (2023)

The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma
por: Zeng, Hui, et al.
Publicado: (2023)

C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients
por: Zhang, Yiyang, et al.
Publicado: (2022)

A Novel Scoring System for Patients with Recurrence of Hepatocellular Carcinoma After Undergoing Minimal Invasive Therapies
por: Wang, Qi, et al.
Publicado: (2019)

Development and validation of a nomogram to predict the recurrence of hepatocellular carcinoma patients with dynamic changes in AFP undergoing locoregional treatments
por: Sun, Yu, et al.
Publicado: (2023)

Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation
por: Zang, Chaoran, et al.
Publicado: (2022)

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
por: Geng, Ruixuan, et al.
Publicado: (2023)

Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review
por: Qiao, Zi-yun, et al.
Publicado: (2021)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study
por: Yang, Xiaozhen, et al.
Publicado: (2021)

Prognosis and Characterization of Immune Microenvironment in Acute Myeloid Leukemia Through Identification of an Autophagy-Related Signature
por: Fu, Denggang, et al.
Publicado: (2021)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma
por: Zhang, Ze, et al.
Publicado: (2023)

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
por: Gou, Miaomiao, et al.
Publicado: (2023)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study
por: Su, Ke, et al.
Publicado: (2022)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
por: Cai, Mingyue, et al.
Publicado: (2022)

Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
por: Liang, Xiaowei, et al.
Publicado: (2023)

Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial
por: Xia, Shengli, et al.
Publicado: (2022)

Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
por: Wei, Fuqun, et al.
Publicado: (2022)

Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
por: Tian, Yuan, et al.
Publicado: (2020)

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
por: Ye, Wenling, et al.
Publicado: (2023)

Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor
por: Song, Yang, et al.
Publicado: (2023)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023)

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma
por: Kong, Xiangyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cjv3spugk8o80ikeu53mvq56rk